Reentered. Breathing pause, clogged gap. Se you at 270! Stoploss 311,5, Short.
Trying to break through MA several times. Daily time fram MACD looking like it wants to cross as well.
Broke out from long downtrending channel this new year. Long-term is bull (not only MACD). Middle-term bull from outbreak. Short-term looks good, held upward trend bottom, bullish hammer and great risk reward right now for a fast trade. Stars alined and easy 8%. Good R/R. Gonna do a bull certificate x5 so smaller position but 40%profit. Stock is a good buy...
PCELL is at a very critical inflection point. This area is where reversals happen so if this level holds, we could see a beautiful reversal towards the upside. Bullish cypher aswell with the beautiful double bottom confirming the low of the harmonic. Bullish divergence as well on the MACD histogram and the RSI. Really good entry right here! Good Luck traders!
Great breakout on decent volume. RSI looking strong.
MACD and RSI indicators crossing down from high levels, Crossing support levels. Fundamentally too expensive. Entry 454, Target 430, Stoploss 456,5. Short.
Taking short position in belief that the Head and Shoulder formation will be effected. Bearish Marubozu/MA-20 cross after resistance level (5/8), charging phase and strong red Candle hopefully starting the fall down to 302. If so, the Head and Shoulder formation is completed and a continued fall down to level of support at 270 is to be expected. Target, 302 and...
ABB went sideways in a wedge pattern since 2009 and broke out to the upside in February of 2021. The stock is in a strong upward trend and is showing confirming downward/sideways flag patterns. After the recent breakout to a new all time high (ATH) the strong trend is likely to continue and the stock seems to be going through a fundamental reevaluation by the...
ISR, Immune System Regulation a small pharmaceutical company with a large appetite where they have very many different ideas and have five drug candidates who are in everything from the early preclinical phase to the clinical phase. This means that they have quite a wide range and a fairly large spread of risk, The chances of success in one or a couple of these...
Overbought market and stock, signs of weakness. Negativ RSI and MACD divergence. Partly a bet against the over bought market (OMX30) Target price, 383 Stoploss, 460 Current price, 444 (13/8) Short.
We can see several reasons that the fall of 2021 will be a tight squeeze for the market. Here are some pointers to look for. 1. Long term rising wedge formation with conjuction and consolidation also in the daily channel, The period between october to december-21 will be the beginning before B-leg starts towards mid MA at 2235 region. 2. We need a B-leg...
Third time hitting down trend-channel roof, week in RSI, MACD with decreasing volume. Hi probability for price dropp. Target, 113 - 109. Stoploss, 123 Current prise, 121 (13/8) Short.
Outbreak up from down trend-channel, triangel formation with big possibility for breakout again? Stoploss - 98 Target - 110 - (122) Current prise, 102, (13/8) Bull.
What comes up must come down. Or up. ATH and looking weak according to Moving average and FIB levels.
Retracement on day chart. Maybe we see a Bullflag? Buy on fib. 61.8% Retracement maybee??
Following an impressive rally from 1330 lows last week price has once again reached and rejected at 1600, after finding support at the 1535 I expect another break-out attempt would clear 1600 and put us on track to previous highs at 1674 and beyond. A retrace towards the 1505-1495 zone might also give a setup next leg up.
After a strong impulsive wave, the stock has been traded in a broadening wedge as a correction. Currentlyu we are waiting for a price movement against the Make or Break levels at 172-178 SEK. If we se a strong breakout to these levels. We'll wait for the first high on the daily timeframe and enter after the breakout targeting the 205-210 levels. The another...
Diamyd chart has repeated this descending wedge pattern, followed by breakouts, thrice during the past three months. A fourth inning is in sight, as they are getting ready to head into the phase III clinical trials (labeled "DIAGNODE-3") of their diabetes vaccine "Diamyd".